Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Evers

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Brain Research Bulletin|December 1, 1989
Lesions of the SDN-POA inhibit sexual behavior of male Wistar ratsF H De Jonge, A L Louwerse, M P Ooms, et al.
Human Genetics|October 1, 1987
Molecular cloning of a pair of human pepsinogen A genes which differ by a Glu----Lys mutation in the activation peptideM P Evers, B Zelle, D S Peeper, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaP A Palmer, J Vinke, P Evers, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
Gene|May 30, 1988
Cloning and sequencing of rhesus monkey pepsinogen A cDNAM P Evers, B Zelle, J P Bebelman, et al.
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
Molecular Biotherapy|September 1, 1990
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experienceH Kirchner, A Körfer, P A Palmer, et al.
The International Journal of Life Cycle Assessment|June 11, 2019
LCA Capability Roadmap: Product System Model Description and RevisionBrandon Kuczenski, Antonino Marvuglia, Miguel F Astudillo, et al.
Human Genetics|May 1, 1989
Family and population studies on the human pepsinogen A multigene familyJ P Bebelman, M P Evers, B Zelle, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Brain Research Bulletin|December 1, 1989
Lesions of the SDN-POA inhibit sexual behavior of male Wistar ratsF H De Jonge, A L Louwerse, M P Ooms, et al.
Human Genetics|October 1, 1987
Molecular cloning of a pair of human pepsinogen A genes which differ by a Glu----Lys mutation in the activation peptideM P Evers, B Zelle, D S Peeper, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaP A Palmer, J Vinke, P Evers, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
Gene|May 30, 1988
Cloning and sequencing of rhesus monkey pepsinogen A cDNAM P Evers, B Zelle, J P Bebelman, et al.
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
Molecular Biotherapy|September 1, 1990
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experienceH Kirchner, A Körfer, P A Palmer, et al.
The International Journal of Life Cycle Assessment|June 11, 2019
LCA Capability Roadmap: Product System Model Description and RevisionBrandon Kuczenski, Antonino Marvuglia, Miguel F Astudillo, et al.
Human Genetics|May 1, 1989
Family and population studies on the human pepsinogen A multigene familyJ P Bebelman, M P Evers, B Zelle, et al.
Pageof 5